Key Takeaways
- Independent commercialization can preserve economics and build enterprise capability; partnership can reduce capital and execution risk.
- Start with the market—prescriber universe, concentration, access burden and competitive intensity shape feasibility.
- Capital is not the only constraint; organizational capability and leadership bandwidth matter.
- Do the commercial work before committing—build the model, then evaluate alternatives.
For an emerging biotechnology company approaching late-stage development, few strategic decisions carry greater implications than whether to commercialize independently.
Going alone can preserve economics and build long-term enterprise capability. Partnering can reduce capital requirements and execution risk.
Neither strategy is universally correct. The decision should begin with a realistic understanding of what commercialization actually requires.
Executive opinion paper
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
